Clinical utilization of cinacalcet in hypercalcemic conditions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 4, 2011, Pages 517-528

  Messa, Piergiorgio ^a   Alfieri, Carlo ^a   Brezzi, Brigida ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

calcium sensing receptor; cinacalcet; hypercalcemia; parathyroid hormone; primary hyperparathyroidism; renal transplantation

Indexed keywords

AM 19; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CALCIMIMETIC AGENT; CALCINEURIN INHIBITOR; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; CYCLOSPORIN A; CYTOCHROME P450 2D6; DEXAMETHASONE; DIURETIC AGENT; DRUG METABOLITE; INFUSION FLUID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHATE; TACROLIMUS; UNCLASSIFIED DRUG; VITAMIN D;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM TRANSPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG UTILIZATION; GENE MUTATION; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MULTIPLE ENDOCRINE NEOPLASIA; MYELOMA; NEONATAL SEVERE HYPERPARATHYROIDISM; NEPHROLITHIASIS; PARATHYROIDECTOMY; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PREGNANCY; PRIMARY HYPERPARATHYROIDISM; PROTEIN EXPRESSION; PUERPERIUM; SECONDARY HYPERPARATHYROIDISM;

CALCIMIMETIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; HYPERPARATHYROIDISM, SECONDARY; KIDNEY TRANSPLANTATION; NAPHTHALENES; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS;

EID: 79952925496     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.562196     Document Type: Article

References (62)

1. Chang W, Shoback D. Extracellular Ca2+ sensing receptors -an overview. Cell Calcium 2004;35:183-96 (Pubitemid 38292362)
2. Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-45 (Pubitemid 30429892)
3. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46:58-67 (Pubitemid 40852012)
4. Bushinsky DA, Monk RD. Electrolyte quintet: calcium. Lancet 1998;352:306-11
5. Messa P, Alfieri C, Brezzi B. Cinacalcet: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol 2008;4(12):1551-60
6. House MG, Kohlmeier L, Chattopadhyay N, et al. Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J Bone Miner Res 1997;12:1959-70 (Pubitemid 27524473)
7. Ye CP, Yamaguchi T, Chattopadhyay N, et al. Extracellular calcium-sensingreceptor (CaR)-mediated opening of an outward K (+) channel in murine MC3T3-E1 osteoblastic cells: evidence for expression of a functional CaR. Bone 2000;27(1):21-7 (Pubitemid 30365073)
8. Dvorak MM, Riccardi D. Ca2+ as an extracellular signal in bone. Cell Calcium 2004;35(3):249-55
9. Tu Q, Pi M, Karsenty G, et al. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto Gcm2 null background. J Clin Invest 2003;111:1029-37 (Pubitemid 36397479)
10. Kos CH, Karaplis AC, Peng JB, et al. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 2003;111:1021-8 (Pubitemid 36397478)
11. Rodriguez L, Tu C, Cheng Z, et al. Expression and functional assessment of an alternatively spliced extracellular Ca2+-sensing receptor in growth plate condrocytes. Endocrinology 2005;146:5294-303 (Pubitemid 41653042)
12. Chang W, Tu C, Chen TH, et al. The extracellular Calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Science Signal 2008;1:1-12
13. Kantham L, Quinn SJ, Egbuna OI, et al. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Renal Physiol 2009;297:E915-23
14. Egbuna OI, Quinn SJ, Kantham L, et al. The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. Am J Physiol Renal Physiol 2009;297:F720-8
15. Marie PJ The calcium-sensing receptor in bone cells. a potential therapeutic target in osteoporosis. Bone 2010;46:571-6
16. Padhi D, Salfi M, Harris RZ. The Pharmacokinetics of cinacalcet are unaffected following consumption of high-and low-fat meals. Am J Ther 2007;14:235-40 (Pubitemid 46791558)
17. Kumar GN, Sproul C, Poppe L, et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004;32:1491-500 (Pubitemid 39564571)
18. Padhi D, Harris RZ, Salfi M, et al. Pharmacokinetics and pharmacodynamic of cinacalcet in hepatic impairment: phase I, open-label, parallel group, single-dose, single-centre study. Clin Drug Invest 2008;28(10):635-43
19. Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 2007;46:495-501 (Pubitemid 46827858)
20. Nakashima D, Takama H, Ogasawara Y, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of destromethorphan: in vitro and clinical studies. J Clin Pharmacol 2007;47:1311-19 (Pubitemid 47459660)
21. Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamic, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004;44:1070-6 (Pubitemid 39556487)
22. Padhi D, Harris R. Clinical Pharmacokinetic and Pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 2009;48:303-11
23. Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and Pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 2008;8:803-10 (Pubitemid 351347748)
24. Kamar N, Gennero I, Spataru L, et al. Pharmacodynamic effects of cinacalcet after kidney transplantation: once-versus twice-daily dose. Nephrol Dial Transplant 2008;23:3720-6
25. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61
26. Kruse AE, Eisenberger U, Frey FJ, et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20:1311-14 (Pubitemid 41435024)
27. Serra AL, Schwarz AA,Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20:1315-19 (Pubitemid 41430604)
28. Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008;23:1048-53 (Pubitemid 351767545)
29. Maass E, Mueller GA, Heller T, Koziolek MJ. Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. Transplant Proc 2007;39:3468-70 (Pubitemid 350251449)
30. Christians U, Kohlhaw K, Budniak J, et al. Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity. Eur J Clin Pharmacol 1991;41:285-90
31. Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998;54:1704-13 (Pubitemid 28502914)
32. Evenepoel P, Bammens B, Claes K, et al. Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol 2010;11:2085-92
33. Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5(8):1934-41 (Pubitemid 41039868)
34. Pinheiro HS, Camara NO, Osaki KS, et al. Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival. Am J Transplant 2005;5(2):323-9 (Pubitemid 40179519)
35. Evenepoel P, Claes K, Kuypers DR, et al. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007;22(6):1730-7 (Pubitemid 47073776)
36. Kandil E, Florman S, Alabbas H, et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci 2010;339:420-4
37. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24(3):982-9
38. Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010. [Epub ahead of print]
39. Gomez Marques G, Obrador Mulet A, Vilar Gimeno A, et al. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant Proc 2009;41(6):2139-43
40. Copley JB, Germain M, Stern L, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc 2010;42:2503-8
41. Borchhardt KA, Heinzl H, Mayerwoger E, et al. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008;86:919-24
42. Evenepoel P, Naesens M, Claes K, et al. Tertiary ?hyperphosphatoninism? accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007;7:1193-200 (Pubitemid 46643105)
43. Rojas E, Carlini RG, Clesca P, et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003;63:1915-23 (Pubitemid 36513342)
44. Bergua C, Torregrosa JV, Fuster D, et al. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008;86(3):413-17
45. Borchhardt KA, Diarra D, Sulzbacher I, et al. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol 2010;31:482-9
46. Bilezikian JP, Khan AA, Potts JT Jr. Third international workshop on the management of asymptomatic primary hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-9
47. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-9 (Pubitemid 38033028)
48. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41 (Pubitemid 40116646)
49. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009;94:4860-7
50. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 2008;57(4):517-21 (Pubitemid 351317967)
51. Iglesias P, Ais G, Gonzalez A, et al. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. Am J Med Sci 2008;335:111-14 (Pubitemid 351253406)
52. Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2766-72
53. Falchetti A, Cilotti A, Vaggelli L, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 2008;4:351-7 (Pubitemid 351733458)
54. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010. [Epub ahead of print]
55. Shangold MM, Dor N, Welt SI, et al. Hyperparathyroidism and pregnancy: a review. Obstet Gynecol Surv 1982;37:217-28 (Pubitemid 14247394)
56. Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv 2002;57:365-76 (Pubitemid 34734370)
57. Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J Pediatr Endocrinol Metab 2009;22:741-9
58. Fanari Z, Kadikoy H, Haque W, et al. Medical management of primary hyperparathyroidism with concomitant multiple myeloma. Intern Med 2010;49:581-4
59. Lietman SA, Tenenbaum-Rakover Y, Jap TS, et al. A novel loss-of-function mutation, Gln459Arg, of the calcium-sensing receptor gene associated with apparent autosomal recessive inheritance of familial hypocalciuric hypercalcemia. J Clin Endocrinol Metab 2009;94:4372-9
60. Nanjo K, Nagai S, Shimizu C, et al. Identification and functional analysis of novel calcium-sensing receptor gene mutation in familial hypocalciuric hypercalcemia. Endocr J 2010;57:787-92
61. Timmers HJ, Karperien M, Hamdy NA, et al. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 2006;260:177-82 (Pubitemid 44051343)
62. Lu JY, Yang Y, Gnacadja G, et al. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J Pharmacol Exp Ther 2009;331:775-86